Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.

Date publication

août 2018

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FUMET Jean-David

Tous les auteurs :
Fumet JD, Wickre M, Jacquot JP, Bizollon MH, Melis A, Vanoli A, Viel E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30126360

Résumé

Metastatic breast cancer (MBC) rest an incurably disease associated with bad prognosis and a median overall survival of 23-31 months. There are several treatment options including chemotherapy and sometimes endocrine therapy. Currently, there is no standard treatment for patients with MBC who have already benefited from anthracyclines and taxanes therapy. Many drugs like capecitabine, eribulin, gemcitabine, vinorelbin and liposomal doxorubicin are conventionally used as monotherapy. One important complication from MBC is life threating visceral crisis that needs a fast-effective treatment.

Mots clés

Breast cancer, Eribulin, Lymphangitic carcinomatosis, Visceral crisis

Référence

BMC Cancer. 2018 Aug 20;18(1):839